23 December 2016
Pfizer Inc, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have completed the last stage of negotiations for a long-term strategic partnership designed to transfer the rights and technologies for the production of more than 30 life-saving and essential drugs from the Pfizer product portfolio. The deal will enable Pfizer and NovaMedica to improve the health of patients in Russia and modernize the Russian pharmaceutical industry.
NovaMedica prepares to launch the new drug development laboratories
10 November 2016
Russian pharmaceutical company NovaMedica launches R&D laboratories as part of its Technology Center project for the development and pilot production of innovative drugs. The facilities are designed to address the most challenging scientific tasks based on the state-of-the-art platforms incorporating nanotechnologies. The project investment totals $15m.
03 October 2016
Four NovaMedica executives are among the business leaders listed in the Top-1000 Russian Managers rating released annually by the Managers Association of Russia and Kommersant Publishing House.
NovaMedica Strengthens its Team
27 July 2016
Russian pharmaceutical company NovaMedica announces strengthening of its team. Elena Ilyina formerly holding one of the key positions in Sun Pharma (Ranbaxy) Russia is appointed as Vice President, Business Development.
Photo: Pfizer and NovaMedica announce a strategic partnership in Russia
13 July 2016
Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.
Pfizer and NovaMedica announce a strategic partnership in Russia
13 July 2016
Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region.
NovaMedica is starting construction of R&D Center for drug development using nanotechnologies
15 December 2015
NovaMedica, a Russian pharmaceutical company, is starting construction of R&D Center for innovative drug development and pilot production in Moscow. This Center will include laboratories and production areas equipped with state-of-the-art process equipment that has never been used in the Russian pharmaceutical industry before. The total investments are estimated approximately $15 million.
NovaMedica is sharing knowledge
29 September 2015
NovaMedica actively involved in RNOF-2015 (Russian National Ophthalmological Forum) that took place in Moscow, September 23, 2015. This is one of the most important educational events in ophthalmology.
22 September 2015
September 17, 2015, Moscow held IBD School (Inflammatory Bowel Disorder School) chaired by the head gastroenterologist of the Moscow Region, Professor Elena Belousova. NovaMedica was the general partner of this educational event that brought together over 100 gastroenterologists from Moscow and other regions of Russia.
NovaMedica opens the program of scientific-practical events for Russian gastroenterologists
16 July 2015
Russian pharmaceutical company NovaMedica takes an active part in the V Baikal Forum on Inflammatory Bowel Diseases (IBD), which befalls from 16 to 18 of July in Irkutsk. Participating in this event NovaMedica opens a series of scientific and practical programs for the professional community of gastroenterologists.
Grand finale from a veritable stalwart of neuroscience
09 November 2023
Battle of pharma advocates – in search of the ideal migraine therapy
09 November 2023
31 October 2023
Long COVID study expanded across Europe
30 November 2023
Ethical, Regulatory, and Operational Considerations for Cell and Gene Therapy Research in Children
30 November 2023
Prevention, Treatment for Migraine Rapidly Evolves, Calling for Development of Novel Drugs
29 November 2023
Imaging AI hogs the spotlight at RSNA, with debuts from GE, Siemens, Philips
29 November 2023